A
Anna Kohn
Researcher at Università Campus Bio-Medico
Publications - 81
Citations - 3488
Anna Kohn is an academic researcher from Università Campus Bio-Medico. The author has contributed to research in topics: Infliximab & Ulcerative colitis. The author has an hindex of 31, co-authored 79 publications receiving 3094 citations.
Papers
More filters
Journal Article
An antibiotic regimen for the treatment of active Crohn's disease : a randomized, controlled clinical trial of metronidazole plus ciprofloxacin
TL;DR: In this article, the efficacy and safety of a combination of metronidazole and ciprofloxacin, compared with methylprednisolone, in treating 41 consecutive patients with active Crohn's disease (CD) were investigated.
Journal ArticleDOI
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
Mario Cottone,Anna Kohn,Marco Daperno,Alessandro Armuzzi,Luisa Guidi,Renata D'Incà,Fabrizio Bossa,Erika Angelucci,Livia Biancone,Paolo Gionchetti,Sandro Ardizzone,Claudio Papi,Walter Fries,Silvio Danese,Gabriele Riegler,Maria Cappello,Fabiana Castiglione,Vito Annese,Ambrogio Orlando +18 more
TL;DR: Patients older than 65 years treated with TNF inhibitors for IBD have a high rate of severe infections and mortality compared with younger patients or patients of the same age that did not receive these therapeutics.
Journal ArticleDOI
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
William J. Sandborn,Subrata Ghosh,Julián Panés,Ivana Vranic,Wenjin Wang,Wojciech Niezychowski,Severine Vermeire,Olivier Dewit,Harald Peeters,Jiri Stehlik,Tomas Vanasek,David Laharie,Jean-Frederic Colombel,Marc-André Bigard,Marta Varga,Margit Zeher,Janos Novak,Béla Hunyady,Ágnes Salamon,István Rácz,Paolo Gionchetti,Anna Kohn,Cosimo Prantera,Pieter C. F. Stokkers,Maria Slomka,Leszek Paradowski,Tomasz Arlukowicz,Ladislav Kuzela,Boris Baricky,Tibor Hlavaty,Maria Isabel Vera,Jordi Guardiola,Chris Probert,Jonathan Shaffer,Mark R. Fleisher,Ronald E. Pruitt,John Sawyer Goff,John Weber,Raymond Lloyd Bell,Andrew Harrison Zwick,Alexandra Gutierrez,Robert H. Levine,Stephen Brett Hanauer,Lori Ann Lavelle,Ravindranath K. Kottoor,Gerald W. Dryden,Robert Hardi,David Vaughn Glorioso,Prabhakar Swaroop,Scott D. Lee,Teressa Joan Patrick,Sheldon Scheinert,Charles A. Sninsky,Seymour Katz,Mark D. Noar,Michael Marion Gaspari,Glenn L. Gordon,Thomas A. Dalton,Douglas Edward Homoky,William Ransom Kilgore,Joel A. Levien,Herbert R. Schneider,Suleman Abdul Moola,Frederik Cornelius Kruger,John P. Wright,Nazimuddin Aboo +65 more
TL;DR: There were no significant differences in the percentage of patients with moderate-to-severe active Crohn's disease who achieved clinical responses (Response-70) or clinical remission after 4 weeks' administration of tofacitinib or placebo twice daily.
Journal ArticleDOI
Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease
Nicholas T. Ventham,Nicholas A. Kennedy,Alex Adams,Rahul Kalla,Simon Heath,KR O’Leary,Hazel E. Drummond,Gordan Lauc,Harry Campbell,Dermot P.B. McGovern,Vito Annese,Vlatka Zoldoš,Iain K. Permberton,Manfred Wuhrer,Manfred Wuhrer,Daniel Kolarich,Daryl L. Fernandes,Evropi Theorodorou,Victoria Merrick,Daniel I. R. Spencer,Richard A. Gardner,Ray Doran,Archana Shubhakar,Ray Boyapati,Igor Rudan,Paolo Lionetti,Irena Trbojević Akmačić,Jasminka Krištić,Frano Vučković,Jerko Štambuk,Mislav Novokmet,Maja Pučić-Baković,Olga Gornik,Angelo Andriulli,Laura Cantoro,G.C. Sturniolo,Gionata Fiorino,Natalia Manetti,Anna Latiano,Anna Kohn,Renata D'Incà,Silvio Danese,Ian D. Arnott,Colin L. Noble,Charlie W. Lees,Alan G. Shand,Gwo-Tzer Ho,Malcolm G. Dunlop,Lee Murphy,Jude Gibson,Louise Evenden,Nicola Wrobel,Tamara Gilchrist,Angie Fawkes,Guinevere S. M. Kammeijer,Florent Clerc,Noortje de Haan,Aleksandar Vojta,Ivana Samaržija,Dora Markulin,Marija Klasić,Paula Dobrinić,Yurii S. Aulchenko,Tim van den Heuve,Daisy Jonkers,Marieke Pierik,Simen Vatn,Petr Ricanek,Jørgen Jahnsen,Panpan You,Janne Sølvernes,Anna B. Frengen,Tone Møller Tannæs,Aina Elisabeth Fossum Moen,Fredrik A. Dahl,Jonas Christoffer Lindstrøm,Gunn S. Ekeland,Trond Espen Detlie,Åsa V. Keita,Johan D. Söderholm,Henrik Hjortswang,Jonas Halfvarson,Daniel Bergemalm,Fernando Gomollón,Mauro D'Amato,Leif Törkvist,Fredrik Hjelm,Mats Gullberg,Niklas Nordberg,Anette Ocklind,Erik Pettersson,Daniel Ekman,Mikael Sundell,Eddie Modig,Anne Clémence Veillard,Renaud Schoemans,Dominique Poncelet,Céline Sabatel,Marta Gut,Monica Bayes,C. Casén,Torbjørn Lindahl,Ewa Ciemniejewska,Morten H. Vatn,David C. Wilson,Ivo Gut,Elaine R. Nimmo,Jack Satsangi +107 more
TL;DR: Site-specific DNA methylation changes in IBD relate to underlying genotype and associate with cell-specific alteration in gene expression, andSeparated cell data shows that IBD-associated hypermethylation within the TXK promoter region negatively correlates with gene expression in whole-blood and CD8+ T cells, but not other cell types.
Journal ArticleDOI
Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up
Anna Kohn,Marco Daperno,Alessandro Armuzzi,Maria Cappello,Livia Biancone,Ambrogio Orlando,Angelo Viscido,Vito Annese,Gabriele Riegler,Gianmichele Meucci,M. Marrollo,R. Sostegni,Antonio Gasbarrini,S. Peralta,Cosimo Prantera +14 more
TL;DR: Severe ulcerative colitis is a life‐threatening disorder, despite i.v. glucocorticoids treatment, and infliximab has been proposed as a safe rescue therapy.